PropertyValue
?:abstract
  • Hydroxychloroquine (HCQ) belongs to the class of 4-aminoquinolines It is a hydroxylated version of chloroquine with a similar mechanism of action but rather a safe profile It is primarily an antimalarial drug but has been extensively used for treating rheumatoid arthritis, porphyria, discoid and systemic lupus erythematosus as well Most recently, this drug has found a place in the treatment of COVID-19 with successful results It is relatively a safer drug to treat COVID-19 in pregnant ladies, diabetic and hypertensive patients This molecule has found its successful and safer use as a pediatric drug The World Health Organization (WHO) has listed hydroxychloroquine as an investigational drug for efficacy against SARS-COV-II COVID-19 is spreading at a tremendous rate, and we need a less expensive drug against the virus, especially in countries with high poverty The production cost of this drug is very low, and so is its retail cost These collective advantages of hydroxychloroquine make it a suitable, effective, safer, and readily available drug candidate for COVID-19 patients
is ?:annotates of
?:creator
?:journal
  • International_Journal_of_Pharmaceutical_Sciences_and_Research
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Hydroxychloroquine (HCQ) as an emerging and promising drug candidate in Covid-19 pandemic - a systematic review
?:type
?:who_covidence_id
  • #922969
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/gdwr3xq3>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/gdwr3xq3>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all